Novantrone Proposed Dosing For MS Could Lead To Two-Year Treatment Limit
Executive Summary
Immunex should study Novantrone at lower doses and a higher cumulative dose to overcome the limitation of a potential two-year cap on use of the mitoxantrone drug for treatment in multiple sclerosis, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee and the agency suggested Jan. 28.
You may also be interested in...
Immunex Novantrone For Multiple Sclerosis Will Be Promoted By MS Society
Immunex is partnering with the National Multiple Sclerosis Society on educational initiatives to promote Novantrone directly to physicians and consumers, the company said following the Oct. 13 approval of the product for advanced or chronic MS.
Immunex Novantrone For Multiple Sclerosis Will Be Promoted By MS Society
Immunex is partnering with the National Multiple Sclerosis Society on educational initiatives to promote Novantrone directly to physicians and consumers, the company said following the Oct. 13 approval of the product for advanced or chronic MS.
Immunex Novantrone For MS May Cost $5,107 Per Year, Lewin Study Finds
The estimated cost of Immunex' Novantrone for treatment of multiple sclerosis is $5,107 per year excluding the cost of cardiac monitoring, according to a Lewin Group analysis released March 14.